ArticleColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland2026
Platelet-rich fibrin matrix as treatment for complex anal fistulae: A 3-year experience at a tertiary centre.
Article in Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimTreatment of complex anal fistulae remains a significant challenge for physicians and patients. A sphincter-preserving technique with bioactive platelet-rich fibrin matrix is one option. This three-year study aimed to evaluate the efficacy of bioactive platelet-rich fibrin matrix in treating complex anal fistulae.
methodThis retrospective study analysed data from 2019 to 2022 of patients diagnosed with complex anal fistulae treated with a platelet-rich fibrin matrix at a tertiary centre. Endoanal ultrasound was used to morphologically characterize fistulas using Park's classification. Pearson's chi-squared and Kaplan-Meier (log-rank) analyses were used to evaluate between-group differences.
resultsA total of 213 patients were included in the study (181 with cryptoglandular fistulae and 32 with Crohn's disease-associated fistulae) with a median follow-up of 6.6 months (range 0.5-67.1 months). Cavities and secondary tracts were identified in 14.6% and 34.7% of the patients, respectively. External opening closure occurred in 32% after one procedure and 43% cumulatively after a second intervention. Healing rates did not differ statistically by aetiology or fistula location. Cavities and secondary tracts were associated with failure. During follow-up, 23% of the secondary tracts healed, whereas cavities derived no significant benefit from the intervention. No serious complications were reported.
conclusionPlatelet-rich fibrin matrix is a simple and safe sphincter-preserving technique that achieves reasonably good results in the treatment of cryptoglandular and Crohn's disease-associated fistulae. While secondary tracts may respond well, further research is required to optimize the management of fistulae associated with cavities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.